Trials / Active Not Recruiting
Active Not RecruitingNCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CagriSema (Cagrilintide B and Semaglutide I) | Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector. |
| DRUG | Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector. |
Timeline
- Start date
- 2025-01-29
- Primary completion
- 2026-08-21
- Completion
- 2026-08-21
- First posted
- 2025-01-29
- Last updated
- 2025-12-05
Locations
54 sites across 7 countries: United States, Canada, Denmark, France, Norway, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06797869. Inclusion in this directory is not an endorsement.